Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

Adriano M. Pellicelli, Valeria Pace Palitti, Pascal Vignally, Francesca Ceccherini-Silberstein, Massimo Siciliano, Valerio Giannelli, Alessandra Moretti, Pierluigi Tarquini, Gaetano Scifo, Vincenzo Messina, Antonio Ascione, Antonio Izzi, Massimo Marignani, Cecilia D'Ambrosio, Lucia Fondacaro, Giuseppe M. Ettorre, Pasquale Ialongo, Rodolfo Sacco, Carlo F. Perno, Giorgio Barbarini

Research output: Contribution to journalArticlepeer-review

Abstract

Background & Aims: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. Methods: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. Results: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were ≥65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged <65 years and 97.7% (130/133) of those ≥65 years. Diabetes was the most common comorbidity in patients ≥65 years compared to younger patients (26.3% vs 12.4% P<.003). The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35.3% vs 19.9% P<.004). Conclusions: Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis.

Original languageEnglish
JournalLiver International
DOIs
Publication statusAccepted/In press - Jan 1 2016

Keywords

  • Cirrhosis
  • Elderly
  • Genotype 1
  • Hepatitis C
  • Simeprevir
  • Sofosbuvir

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study'. Together they form a unique fingerprint.

Cite this